Comparative Pharmacology
Head-to-head clinical analysis: SODIUM TETRADECYL SULFATE versus VARITHENA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM TETRADECYL SULFATE versus VARITHENA.
SODIUM TETRADECYL SULFATE vs VARITHENA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
Selective α1-adrenergic receptor antagonist, causing relaxation of smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia.
1% to 3% solution, 0.1-0.5 mL per injection, intravenous, as needed for sclerotherapy; maximum 10 mL per session.
250 mg orally once daily
None Documented
None Documented
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-30 hours in moderate renal impairment (CrCl <50 mL/min).
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Primarily renal excretion of unchanged drug (65%) and hepatic metabolism (35%) with biliary elimination of metabolites; total renal clearance accounts for 70% of elimination.
Category C
Category C
Sclerosing Agent
Sclerosing Agent